| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/04/2002 | EP1235907A1 6 human secreted proteins |
| 09/04/2002 | EP1235905A2 Device for extraction of nucleic acids |
| 09/04/2002 | EP1235900A1 Microparticle-based transfection and activation of dendritic cells |
| 09/04/2002 | EP1235860A2 G-protein coupled receptors |
| 09/04/2002 | EP1235858A1 Use of the insulin-like-growth factor i isoform mgf for the treatment of neurological disorders |
| 09/04/2002 | EP1235846A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 09/04/2002 | EP1235845A2 24 human secreted proteins |
| 09/04/2002 | EP1235844A1 28 human secreted proteins |
| 09/04/2002 | EP1235843A1 26 human secreted proteins |
| 09/04/2002 | EP1235842A1 Rna interference pathway genes as tools for targeted genetic interference |
| 09/04/2002 | EP1235837A1 Kringle domain-containing polynucleotides, polypeptides, and antibodies |
| 09/04/2002 | EP1235597A2 Nucleic acid delivery system |
| 09/04/2002 | EP1235596A2 Use of lytic toxins and toxin conjugates |
| 09/04/2002 | EP1235594A2 Inhibition of secretion from non-neuronal cells |
| 09/04/2002 | EP1235536A1 Medical device |
| 09/04/2002 | EP1098632A4 Charge reversal of polyion complexes |
| 09/04/2002 | EP1009425B1 Use of Latency Associated Peptide for the manufacture of a medicament for increasing wound healing. |
| 09/04/2002 | EP0969828B1 Butyrate prodrugs derived from lactic acid |
| 09/04/2002 | EP0755443B1 Tissue-specific enhancer active in prostate |
| 09/04/2002 | EP0711355B1 Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors |
| 09/04/2002 | EP0702723B1 Biocompatible implant for the expression and secretion in vivo of a therapeutical compound |
| 09/04/2002 | CN1367839A Paramyxoviruses having modified transcription initiation sequence |
| 09/04/2002 | CN1367832A Ehrlichia canis genes and vaccines |
| 09/04/2002 | CN1367830A Cancer associated antigens and uses therefor |
| 09/04/2002 | CN1367828A Oligonucleotides for inhibiting expression of human eg5 |
| 09/04/2002 | CN1367826A Method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 09/04/2002 | CN1367790A Moraxella cattarrhalis BASB114 polypeptide antigens and uses thereof |
| 09/04/2002 | CN1367704A Agent for gene therapy and for prevention of metastases, as well as for gene therapy of tumors |
| 09/04/2002 | CN1367021A DNA vaccine for foot-and -mouth disease |
| 09/04/2002 | CN1367020A Nucleic acid vaccine capable of being high-effectively and safely expressed |
| 09/03/2002 | US6444871 Expression vector for use in the treatment and prevention of viral diseases |
| 09/03/2002 | US6444806 Complexing |
| 09/03/2002 | US6444803 Bone mineralization proteins, DNA, vectors, expression systems |
| 09/03/2002 | US6444802 Human aminopeptidase |
| 09/03/2002 | US6444801 Transcriptional inhibitor protein and the encoding DNA |
| 09/03/2002 | US6444800 Human gastric cancer antigen gene and gastric cancer antigen protein |
| 09/03/2002 | US6444790 Peptidoglycan recognition proteins |
| 09/03/2002 | US6444650 Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| 09/03/2002 | US6444465 Antinsense modulation of Her-1 expression |
| 09/03/2002 | US6444464 Antisense modulation of E2F transcription factor 2 expression |
| 09/03/2002 | US6444444 Immunogenic composition, comprising at least one nucleic acid fragment as an active component thereof and vector for transformation of a host comprising the nucleic acid fragment |
| 09/03/2002 | US6444443 Gene |
| 09/03/2002 | CA2232985C Methods for treating cancers and restenosis with p21 |
| 09/03/2002 | CA2223566C Method for identifying or isolating a molecule and molecules identified thereby |
| 09/03/2002 | CA2001815C Products and methods for controlling the suppression of the neoplastic phenotype |
| 08/29/2002 | WO2002066989A2 Diagnostics, assay methods and amelioration of muscular dystrophy symptoms |
| 08/29/2002 | WO2002066654A2 Drug metabolizing enzymes |
| 08/29/2002 | WO2002066648A2 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |
| 08/29/2002 | WO2002066647A2 Type 2 ctokine receptor and nucleic acids encoding same |
| 08/29/2002 | WO2002066646A2 Neurotransmission-associated proteins |
| 08/29/2002 | WO2002066636A2 T cell receptor variants expressed in mesenchymal cells and uses thereof |
| 08/29/2002 | WO2002066629A2 Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| 08/29/2002 | WO2002066626A2 Regulation of human mut/nudix nucleoside triphosphate pyrophosphohydrolase |
| 08/29/2002 | WO2002066624A2 Novel human protease and polynucleotides encoding the same |
| 08/29/2002 | WO2002066620A2 Pigmentary epithelium cell of the eye, the production thereof and the use of the same for treating diseases of the eye or of the central nervous system |
| 08/29/2002 | WO2002066601A2 Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam2 |
| 08/29/2002 | WO2002066512A1 Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| 08/29/2002 | WO2002066490A2 Cationic sterol derivatives, ph-sensitive liposomes comprising cationic sterol derivatives and method for loading liposomes with active substances |
| 08/29/2002 | WO2002066489A2 Amphoteric sterols and the use thereof in the production of ph-sensitive liposomes |
| 08/29/2002 | WO2002066488A1 Compositions and methods relating to prostate specific genes and proteins |
| 08/29/2002 | WO2002066078A2 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002066077A2 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002066076A1 A method of treatment and agents useful for same |
| 08/29/2002 | WO2002066072A1 Methods for the treatment and diagnosis of prostate cancer based on p75ntr tumor |
| 08/29/2002 | WO2002066070A1 Pharmaceutical compositions containing decoy and method of using the same |
| 08/29/2002 | WO2002066069A1 Remedies for inflammatory/tumor diseases |
| 08/29/2002 | WO2002066068A2 Method of treating neurological diseases |
| 08/29/2002 | WO2002066049A1 Agents for plasmic change |
| 08/29/2002 | WO2002066010A1 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002065989A2 Aminoglycoside treatment for lysosomal storage diseases |
| 08/29/2002 | WO2002042316A3 Pna analogues |
| 08/29/2002 | WO2002022795A3 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 08/29/2002 | WO2002020786A3 Kinase d interacting protein |
| 08/29/2002 | WO2002020723A3 Compositions and methods for targeting peptides in humans in vivo |
| 08/29/2002 | WO2002012460A3 Isolation of a human amine oxidase-like protein |
| 08/29/2002 | WO2002010403A3 Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
| 08/29/2002 | WO2002010388A3 C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF |
| 08/29/2002 | WO2001088135A3 G-protein coupled receptor proteins and nucleic acids encoding same |
| 08/29/2002 | WO2001079284A3 Therapeutic compounds and methods for formulating v3, a versican isoform |
| 08/29/2002 | WO2001070816A3 Ecdysone receptor-based inducible gene expression system |
| 08/29/2002 | WO2001048164A3 Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure |
| 08/29/2002 | WO2001005373A9 Methods and apparatus for preparation of lipid vesicles |
| 08/29/2002 | WO2001004629A9 E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death |
| 08/29/2002 | WO2001000247A9 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 08/29/2002 | WO2000066737A9 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY |
| 08/29/2002 | WO2000063245A9 Variant of the plasmodium merozoite surface protein (msp-1) and vaccine comprising said variant |
| 08/29/2002 | WO2000056866A9 Akt-3 nucleic acids, polypeptides, and uses thereof |
| 08/29/2002 | WO2000034474A9 Growth factor homolog zvegf3 |
| 08/29/2002 | WO2000034447A9 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 08/29/2002 | WO2000023569A9 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 08/29/2002 | US20020120948 Modulating gene expression by regulation of cell proliferation; regulated transgene expression in lymphocytes by selective increase in the number of lymphocytes upon exposure to an antigen |
| 08/29/2002 | US20020120123 Human vascular endothelial growth factor 2 |
| 08/29/2002 | US20020120121 Antisense therapy of cancer; Inhibitors of Apoptosis Proteins (IAPs) and an additional related antiapoptotic protein, NAIP; |
| 08/29/2002 | US20020120120 Nucleic acid sequences of genes encoding high mobility group proteins and uses thereof |
| 08/29/2002 | US20020120117 Polynucleotide that exhibits urothelial cell-specific transcriptional response element (TRE) activity; adenoviral vectors which replicate preferentially in urothelial cells; treating bladder cancer for example |
| 08/29/2002 | US20020120103 17 human secreted proteins |
| 08/29/2002 | US20020120100 Peptide transporters that specifically target certain cell types for the delivery of drugs and therapeutic agents |
| 08/29/2002 | US20020119946 Formative agent of protein complex |
| 08/29/2002 | US20020119945 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 08/29/2002 | US20020119943 Novel mammalian gene,bcl-w, belongs to the bcl-2 family of apoptosis-controlling genes |